Stryker Sells U.S. Spinal Implants Business

Stryker to Sell its U.S. Spinal Implants Business
“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.”
Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business
“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.”
Stryker to sell spine business: 8 notes for ASCs
Here are eight things for ASCs to know about the sale: 1. Stryker's U.S. spine segment will be sold to investment firm Viscogliosi Brothers. 2. That group will create VB Spine, which will be a strategic partner to Stryker with exclusive access to the company's Mako Spine and Copilot technology.
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
Stryker Corporation SYK recently announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space,
Stryker to Sell Spinal Implants Business to Viscogliosi Brothers
Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi Brothers to create a newly formed company called VB Spine. The medical technology company said Tuesday the New York City-based Viscogliosi Brothers specializes in neuro-musculoskeletal treatments.
Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street
Lake Street analyst Brooks O’Neil notes that Stryker (SYK) announced a definitive agreement for the sale of its U.S. spinal implants business
Stryker to sell spinal implants business
Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.
Stryker price target raised to $413 from $409 at Truist
Truist raised the firm’s price target on Stryker (SYK) to $413 from $409 and keeps a Hold rating on the shares. The company remains a top-tier ...
Hosted on MSN23h
Stryker price target raised to $427 from $384 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Stryker (SYK) to $427 from $384 and keeps a Neutral rating on the shares ...
Becker's Spine Review9h
California hospital adds Stryker's Q Guidance system
MemorialCare Long Beach Medical Center is the first hospital in California to add Stryker's Q Guidance system with Spine Guidance software, according to a Jan.
Stryker Corporation: Stryker reports 2024 operating results and 2025 outlook
Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% ...
Stryker's SWOT analysis: medical tech giant's stock poised for growth
Stryker Corporation (NYSE:SYK), a leading player in the medical technology industry with a substantial market capitalization of $149 billion, has been making waves with its strong financial ...
Becker's Spine Review1d
Stryker's shoulder robot earns FDA approval
Stryker's Mako shoulder robot earned FDA approval in December, Jason Beach, vice president of finance and investor relations, said in a Jan. 28 earnings call.